SWK Holdings Corp
SWK Holdings Corp is a U.S.-based specialty finance company that provides asset-backed lending and royalty financing to healthcare and life sciences businesses. Its portfolio includes senior secured debt, revenue-interest financings, royalty purchases, and related investment positions, with operations organized around finance receivables and pharmaceutical development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSenior secured loans and revenue-interest assets repaid from borrower cash flows, net sales, or royalties.
Purchased royalty streams tied to licensed pharmaceutical and medical technology products.
Development-stage pharmaceutical assets and related manufacturing or R&D activities.
Minority investments, warrant assets, and other equity-linked positions in portfolio companies.
Asiakkaat
SWK primarily finances healthcare, pharmaceutical, and medical technology companies that need non-dilutive capital tied to product cash flows. It also acquires royalty interests from companies or asset owners seeking upfront liquidity in exchange for future product sales participation. The end markets are specialized, with repayment often linked to prescription drugs, medical devices, or other regulated healthcare products.
Companies that borrow against product revenues, royalties, or other secured assets to fund operations and growth.
Owners of pharmaceutical or medical product royalty streams that sell future cash flows for upfront capital.
Businesses whose product sales generate the revenue interests and royalties that support SWK's assets.
Portfolio companies where SWK holds warrants or equity-linked positions alongside debt or royalty assets.
Strategia
SWK's strategy centers on originating structured healthcare financings and royalty assets that generate contractual cash flows from product sales. The company also manages portfolio turnover through payoffs, sales of royalties, and selective use of warrants or equity-linked positions. Its business model depends on underwriting discipline, monitoring borrower performance, and maintaining a spread between funding costs and asset yields.
This is the core source of contractual cash flow and portfolio growth.
Royalty streams diversify returns beyond traditional lending and can provide long-duration cash flows.
Payoffs, sales, and conversions recycle capital and reduce concentration in aging positions.
Maantiede
SWK is headquartered in the United States and its portfolio is primarily tied to U.S. healthcare and life sciences businesses. The disclosures also indicate some exposure to international sales through royalty streams, but the company does not provide a broad country revenue split in the excerpts provided. Geography matters mainly because borrower cash flows and royalty collections depend on regulated product sales in the U.S. and, in some cases, overseas markets.
Riskit
SWK is exposed to credit risk, borrower performance risk, and valuation risk because its assets are repaid from specialized healthcare cash flows and royalties. Interest-rate changes can affect funding costs and portfolio spreads, while inflation or weaker product demand can reduce borrower ability to pay and lower fair values. The company also faces concentration risk in individual royalty and loan positions, plus accounting sensitivity around fair value estimates and non-accrual assets.
Repayment depends on borrower sales, royalties, and operating performance.
Kohdistuu: Finance receivables and royalty assets
Borrowing costs can rise faster than asset yields on floating/fixed mix portfolios.
Kohdistuu: Revolving credit facility and leveraged investments
A small number of specialized counterparties can drive a large share of returns.
Kohdistuu: Royalty purchases and secured loans
Market and company-specific changes affect unrealized gains/losses and carrying values.
Higher input costs can reduce borrower profitability and repayment capacity.
Kohdistuu: Portfolio companies with limited pricing power
Kirjanpito
Harkinnanvaraiset erätWarrant assets, marketable investments, and some portfolio positions require valuation estimates.
Vaikutus: Can create unrealized gains or losses and change net asset value
Income depends on underlying product sales and contractual royalty terms.
Vaikutus: Can cause uneven quarterly revenue and comparability issues
Troubled loans may stop accruing interest and require write-downs.
Vaikutus: Directly affects interest income and asset carrying values
Some receivables and royalties are classified as held for sale before disposition.
Vaikutus: Changes balance sheet mix and can affect reported revenue timing
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
SS&C Technologies Holdings Inc
SSNC · Services-Prepackaged Software
SS&C Technologies Holdings is a U.S.-based provider of software and software-enabled services for financial services and healthcare organizations.
Scienture Holdings, Inc.
SCNX · Pharmaceutical Preparations
SKK Holdings Ltd
SKK · Water, Sewer, Pipeline, Comm & Power Line Construction
SKK Holdings Ltd is a Singapore-based civil engineering services company focused on subsurface utility works.
SHF Holdings, Inc.
SHFSW · Finance Services
GSK plc
GSK · Pharmaceutical Preparations
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments.
SCWorx Corp.
WORX · Services-Computer Processing & Data Preparation
Päivitetty: 24.9.2026